ReviewFrontiers in immunology2026
The interplay between neuroinflammation and endothelial dysfunction in cerebral small vessel disease.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Association of C-Reactive Protein with Functional Outcome After Acute Ischemic Stroke Across TOAST Subtypes.Journal of clinical medicine · 2026Article
- Review
- Comparative Analysis of the Association of Biomarkers of Endothelial Dysfunction and Systemic Inflammation in Patients with Coronary Artery Disease with the Presence/Absence of Personality Type D.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebral small vessel disease (CSVD) is a leading cause of ischemic stroke and vascular cognitive impairment. Despite well-defined neuroimaging features and a substantial clinical burden, the underlying pathological mechanisms of CSVD remain poorly understood, and effective interventions are still lacking. Current human and experimental evidence suggest that endothelial dysfunction and neuroinflammation are closely coupled and may form a mutually reinforcing process in many CSVD-relevant settings. This review synthesizes available evidence into a working framework in which vascular risk factors promote endothelial phenotypic switching and blood-brain barrier (BBB) dysfunction, thereby facilitating neuroinflammatory activation. Pericytes, astrocytes, and microglia within the neurovascular unit can then amplify barrier injury and inflammatory signaling through context-dependent feedback interactions, including matrix metalloproteinase-mediated proteolysis. In turn, the chronic inflammatory milieu may sustain persistent endothelial dysfunction or alter endothelial responsiveness to subsequent inflammatory stimuli, potentially allowing pathological processes to continue even after the original triggers are attenuated. Based on this evidence-guided framework, we also evaluate therapeutic strategies directed at distinct nodes of the endothelial dysfunction-neuroinflammation network.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.